Unlocking the Future of Immunotherapy with Hybridoma Technology
Hybridoma technology is used in treatment of autoimmune conditions, viral infections and cancer, states a recent narrative review in the American Journal of Biopharmacy and Pharmatceutical Sciences published by Scientific Scholar. The importance of immunotherapeutics based on antibody and hybridoma technologies is revolutionizing the treatment environment and creating new opportunities...
Hybridoma technology is used in treatment of autoimmune conditions, viral infections and cancer, states a recent narrative review in the American Journal of Biopharmacy and Pharmatceutical Sciences published by Scientific Scholar. The importance of immunotherapeutics based on antibody and hybridoma technologies is revolutionizing the treatment environment and creating new opportunities for customized and targeted therapies.
A focused and extremely specific treatments for a wide range of ailments, including cancer, autoimmune disorders, and infectious diseases, immunotherapeutics based on antibody and hybridoma technologies have completely changed the practice of medicine.
By harnessing the immune system’s strength and fusing it with cutting-edge biotechnology, this method creates monoclonal antibodies (mAbs), which are therapeutic agents that mAbs are molecules created in a laboratory that resembles the immune system’s naturally occurring antibodies.
This research offers a thorough analysis of immunotherapeutics with a focus on hybridomas. It describes how focused and precise treatments for a variety of illnesses, such as cancer, autoimmune disorders, and infectious diseases, have been made possible by immunotherapeutics, which are based on antibody and hybridoma technology.
The hybridoma technology process, is a heterogeneous population of cells that produce unique mAbs are created by combining immortalized myeloma cells with B lymphocytes. To isolate and create drug formulations, the hybridoma cells that produce the desired antibodies are chosen and grown in large numbers.
Reference: Vaghela AR, Ganatra TH. A detailed review of immunotherapeutics with a special emphasis on hybridoma technology. Am J Biopharm Pharm Sci. 2024;4:2. doi: 10.25259/AJBPS_13_2023
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd